Decay accelerating activity of complement receptor type 1 (CD35) - Two active sites are required for dissociating C5 convertases

被引:83
作者
Krych-Goldberg, M
Hauhart, RE
Subramanian, VB
Yurcisin, BM
Crimmins, DL
Hourcade, DE
Atkinson, JP
机构
[1] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Pathol, Div Lab Med, St Louis, MO 63110 USA
关键词
D O I
10.1074/jbc.274.44.31160
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The goal of this study was to identify the site(s) in CRI that mediate the dissociation of the C3 and C5 convertases. To that end, truncated derivatives of CR1 whose extracellular part is composed of 30 tandem repealing modules, termed complement control protein repeats (CCPs), were generated. Site 1 (CCPs 1-3) alone mediated the decay acceleration of the classical and alternative pathway C3 convertases, Site 2 (CCPs 8-10 or the nearly identical CCPs 15-17) had one-fifth the activity of site 1. In contrast, for the C5 convertase, site 1 had only 0.5% of the decay accelerating activity, while site 2 had no detectable activity. Efficient C5 decay accelerating activity was detected in recombinants that carried both site 1 and site 2, The activity was reduced if the intervening repeats between site 1 and site 2 were deleted. The results indicate that, for the C5 convertases, decay accelerating activity is mediated primarily by site 1. A properly spaced site 2 has an important auxiliary role, which may involve its C3b binding capacity. Moreover, using homologous substitution mutagenesis, residues important in site 1 for dissociating activity were identified. Based on these results, we generated proteins one-fourth the size of CR1 but with enhanced decay accelerating activity for the C3 convertases.
引用
收藏
页码:31160 / 31168
页数:9
相关论文
共 47 条
[1]   Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen [J].
Ahearn, JM ;
Fischer, MB ;
Croix, D ;
Goerg, S ;
Ma, MH ;
Xia, JR ;
Zhou, XN ;
Howard, RG ;
Rothstein, TL ;
Carroll, MC .
IMMUNITY, 1996, 4 (03) :251-262
[2]  
BRODBECK WG, 1998, MOL IMMUNOL, V35, P426
[3]  
CERVONI F, 1993, J IMMUNOL, V151, P939
[4]   COMPLEMENT EVASION STRATEGIES OF MICROORGANISMS [J].
COOPER, NR .
IMMUNOLOGY TODAY, 1991, 12 (09) :327-331
[5]   PRIMATE ERYTHROCYTE-IMMUNE COMPLEX-CLEARING MECHANISM [J].
CORNACOFF, JB ;
HEBERT, LA ;
SMEAD, WL ;
VANAMAN, ME ;
BIRMINGHAM, DJ ;
WAXMAN, FJ .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (02) :236-247
[6]   POLYMORPHISM OF HUMAN-ERYTHROCYTE C3B C4B RECEPTOR [J].
DYKMAN, TR ;
COLE, JL ;
IIDA, K ;
ATKINSON, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (06) :1698-1702
[7]   ROLE OF MEMBRANE RECEPTORS FOR C3B AND C3D IN PHAGOCYTOSIS [J].
EHLENBERGER, AG ;
NUSSENZWEIG, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 1977, 145 (02) :357-371
[8]  
FALLMAN M, 1993, J IMMUNOL, V151, P330
[9]   IDENTIFICATION OF THE MEMBRANE GLYCOPROTEIN THAT IS THE C3B RECEPTOR OF THE HUMAN-ERYTHROCYTE, POLYMORPHONUCLEAR LEUKOCYTE, LYMPHOCYTE-B, AND MONOCYTE [J].
FEARON, DT .
JOURNAL OF EXPERIMENTAL MEDICINE, 1980, 152 (01) :20-30
[10]   HUMAN EOSINOPHILS EXPRESS CR-1 AND CR3 COMPLEMENT RECEPTORS FOR CLEAVAGE FRAGMENTS OF C-3 [J].
FISCHER, E ;
CAPRON, M ;
PRIN, L ;
KUSNIERZ, JP ;
KAZATCHKINE, MD .
CELLULAR IMMUNOLOGY, 1986, 97 (02) :297-306